Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709127 | 1.00 | LMNA (0.41) | LMNAPOLBALDH1A1SCN9ANPC1 | |
| SCHEMBL709307 | 1.00 | LMNA (0.41) | LMNAPOLBALDH1A1SCN9ANPC1 | |
| SCHEMBL419701 | 0.94 | LMNA (0.46) | LMNAPOLBALDH1A1SCN9ARAB9A | |
| SCHEMBL16640 | 0.94 | LMNA (0.46) | LMNAPOLBALDH1A1SCN9ARAB9A | |
| SCHEMBL709637 | 0.94 | LMNA (0.46) | LMNAPOLBALDH1A1SCN9ARAB9A | |
| SCHEMBL20266437 | 0.88 | LMNA (0.36) | LMNAPOLBALDH1A1SCN9AKDM4E | |
| SCHEMBL12747032 | 0.88 | LMNA (0.36) | LMNAPOLBALDH1A1SCN9AKDM4E | |
| SCHEMBL2199578 | 0.82 | ALDH1A1 (0.42) | LMNAPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10682980 | 0.81 | CA2 (0.44) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL26687025 | 0.79 | LMNA (0.49) | LMNAPOLBALDH1A1SCN9ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150994-A1 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | SIERRA ONCOLOGY, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-5736549-A | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE, USED FOR TREATING OR PREVENTING TISSUE REJECTION OR SELECTIVE SUPPRESSION OF MAMMALIAN T-CELL FUNCTION | CHIROSCIENCE LIMITED (GB) | 1998-04-07 | — | — | US | disclosed |
| EP-0784624-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150994-A1 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | CHEK1, CHEK2, CDC7 | LMNA 1869/4885POLB 157/4885ALDH1A1 4400/4885 |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | LMNA 1600/4885POLB 3746/4885ALDH1A1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.